Hepion Pharmaceuticals approved an amendment to its certificate of incorporation to increase the authorized number of shares of Common and Preferred Stock to 750 million and 20 million, respectively, reflecting its capital structure. This move provides the company with greater financial flexibility for potential future transactions, including mergers, acquisitions, and equity financing.